Month: September 2026

September 16, 2026

• SYMPHONY receives ITEA’s highest excellence award for connected healthcare ecosystems
• AI FORSchung is recognized for innovation in AI-powered fiber-optic sensing

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare.

SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for connecting healthcare data, clinical workflows and AI-supported decision tools through open, interoperable ecosystems. AI FORSchung received the ITEA Award of Excellence for Innovation for developing AI-driven methods to compress and analyze large volumes of fiber-optic sensing data. The awards were presented at the ITEA PO Days 2026 in Istanbul, Turkey.

Connecting data and AI around clinical workflows
SYMPHONY developed a reusable, vendor-neutral reference architecture and demonstrated connected healthcare ecosystems across four clinical areas: prostate cancer, aortic aneurysm, atrial fibrillation and multiple sclerosis with clinical partners including Leiden University Medical Center, Amsterdam University Medical Center and Karolinska University Hospital.

Philips also developed technology within SYMPHONY to automatically segment and measure vascular structures in medical images, supporting the assessment and follow-up of aortic aneurysms. The resulting functionality has received FDA clearance and CE marking and is included in AV Vascular, a part of the Philips AV Cardiovascular Suite.

“Healthcare AI creates the greatest value when it can work with the information and clinical workflows that care teams already depend on,” said Sanjay Gandhi, Head of Medical Affairs & Clinical Partnerships at Philips. “SYMPHONY shows what becomes possible when healthcare providers, researchers and technology companies build around open standards and clinical pathways rather than isolated applications.”

This real-world implementation was demonstrated through many close collaborations including the one between Philips and Leiden University Medical Center (LUMC), where standards-based integration was the focus.

“Together with Philips, the LUMC demonstrated in SYMPHONY how vendor-neutral, standards-based integration of clinical data, imaging and applications, including the AV Vascular Segmentation solution, can support real clinical workflows,” said Jouke Dijkstra, Associate Professor, Vascular and Molecular Imaging at LUMC. The project created a reusable foundation for deploying innovative digital health solutions, also tailored towards AI algorithm integration, across institutions and disease areas.”

Making growing sensing datasets more manageable
Fiber Optic RealShape (FORS) technology is used to support medical device navigation during image-guided procedures, generating large volumes of position data that need to be stored and processed efficiently. Within AI FORSchung, researchers developed new methods to make these data volumes easier to manage, demonstrating that FORS position data could be compressed more than 20 times while maintaining performance within the evaluated datasets.

“The challenge extends well beyond healthcare,” said Ahmet Ekin, Senior Designer at Philips. “Fiber-optic sensing is also used to monitor critical infrastructure such as pipelines, bridges and tunnels, where continuous monitoring generates substantial volumes of data. By developing approaches that can be applied across healthcare, utilities and civil infrastructure, AI FORSchung demonstrated how advances in one field can help address shared data challenges in another.

Both projects were conducted within ITEA, the Eureka Research, Development and Innovation Cluster on software innovation, funded by multiple national authorities including the Netherlands Enterprise Agency (RVO).

Additional information about SYMPHONY can be found here: https://itea4.org/project/symphony.html; https://symphony-iteaproject.eu/

Additional information about AI FORSchung can be found here: https://itea4.org/project/ai-forschung.html

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Winners of the 2026 ITEA Awards of Excellence

Stellantis to Unveil New Mobility Vision with Nine Concept Cars, October 12-18 at Paris Motor Show

• Stellantis will showcase nine concept cars from eight brands and more than 60 vehicles at Paris Motor Show
• Iconic brands: Alfa Romeo, Citroën, DS Automobiles, FIAT, Lancia, Leapmotor, Opel and PEUGEOT will welcome visitors in Hall 4
• The event’s largest booth, spanning more than 5,000 square meters, will offer an interactive, multisensory experience that signals Stellantis’ renewed ambition
• International premieres will include the DS N°7 premium compact SUV; the all-new Fiat Grizzly; the new Lancia Gamma, marking the brand’s return to the C-UV crossover market; the Leapmotor B03 compact B-segment electric vehicle; the D19, Leapmotor’s state-of-the-art flagship SUV; and the Opel Corsa GSE
• Stellantis CEO Antonio Filosa and Enlarged Europe COO Emanuele Cappellano will attend each brand’s press conference. Ralph Gilles, head of Stellantis Design, and Gilles Vidal, head of Design for Enlarged Europe, will present the Company’s renewed design momentum, while Chief Engineering and Technology Officer Ned Curic will highlight the latest innovations across the Stellantis lineup

AMSTERDAM, September 16, 2026 – Stellantis will showcase nine concept cars and more than 60 vehicles at the Paris Motor Show, October 12-18, underscoring its renewed growth ambitions and continued execution of the FaSTLAne 2030 strategic plan unveiled in May.

Located in Hall 4 of the Porte de Versailles Exhibition Centre, the 5,340-square-meter Stellantis booth – the show’s largest – will feature vehicles spanning from urban micromobility to long-distance travel. The display will highlight the Company’s broad range of powertrain technologies and its commitment to giving customers the freedom to choose how they move.

A Wide Range of Premieres

DS Automobiles celebrates the commercial launch of DS N°7, making its first appearance at an international motor show. New ambassador for comfort and savoir-faire of DS Automobiles, the DS N°7 will be available with both hybrid and fully electric powertrains and offers a driving range up to 740 kms.

FIAT is presenting the new Grizzly and Grizzly Fastback, two complementary SUVs that make family transportation accessible to all. Combining space, versatility and everyday practicality, they give customers the freedom to choose the silhouette that best suits their needs.

Lancia will unveil the new Lancia Gamma, marking the brand’s return to the C-UV crossover market and an important milestone in its relaunch and European development. Designed, developed and produced in Italy at the Stellantis plant in Melfi, the new Gamma embodies the brand’s distinctive interpretation of Italian elegance, combining a refined fastback silhouette with aerodynamic efficiency, generous interior space and everyday versatility.

Leapmotor continues its rapid growth among China’s leading automotive brands, backed by its joint venture with Stellantis. This momentum is reflected in the European premieres of B03, its high-tech compact B-segment EV, and the D19, the brand’s state-of-the-art flagship SUV. Both models embody Leapmotor’s commitment to innovation, showcasing the latest developments in intelligent mobility, advanced connectivity and next-generation electric vehicle technology.

Opel has an exciting lineup planned for visitors. Not only will the German brand present the final design of the Opel GSE 27FE Formula E car and the new Corsa GSE for the first time, the manufacturer has now also confirmed that it will be unveiling its latest concept car in the French capital.

Alfa Romeo will showcase the entire Alfa Romeo lineup, Junior, Tonale, Giulia, Stelvio, 33 Stradale and the iconic Spider “Duetto” from the Alfa Romeo Museum in Arese, celebrating its 60th anniversary.

Citroën returns home, where its story began. The brand arrives in Paris with a fully renewed lineup that remains true to its longstanding values of practicality and ingenious, people-focused solutions and a surprise inspired by the most iconic model in its history.

PEUGEOT will put excitement center stage with all-brand-new concept cars, its latest high-performance production models and groundbreaking innovations such as the Hypersquare and the Polygon concept car. Alongside the full vehicle range, visitors will be able to admire the 9X8 Hypercar, currently competing in the FIA World Endurance Championship, and the new E-208 GTi.  PEUGEOT will unveil its French vision of technology, elegance and sportiness throughout the whole exhibition.

Design and Technology

The unveiling of nine concept cars provides further evidence that Stellantis has regained its traditional creative momentum, moving beyond pure design exercises to the tangible development of vehicles that inspire emotion and desire. Ralph Gilles, Head of Stellantis Design and Gilles Vidal, Head of Design for Enlarged Europe, will present Stellantis’ design vision and strategy, aimed at bringing together the voices of its individual brands into a single, powerful narrative.

To turn creative design into reality, technology is essential. In Stellantis’ vision, technology is made for humans to create products that improve customers’ lives. This philosophy lies at the heart of STLA One, Stellantis’ new modular multi-energy platform. Ned Curic, Chief Engineering and Technology Officer, will outline this vision during a dedicated roundtable discussion on Monday, October 12, from 9:15 a.m. to 9:45 a.m. CEST.

Thanks to these technological innovations, Stellantis is redefining the speed at which vehicles are brought to market. At the same time, Stellantis is building a multi-energy future that combines electrification, software and artificial intelligence in order to preserve customers’ freedom of choice.

To underscore the strategic importance of the event and Stellantis’ commitment to strengthening its position in the global automotive industry, the Company’s delegation will be led by Antonio Filosa, Stellantis CEO, and Emanuele Cappellano, Chief Operating Officer Enlarged Europe. Both executives will attend the comprehensive program of press conferences and panel discussions dedicated to the Group’s brands.

Below is the schedule of press conferences, all taking place at Hall 4 on the morning of October 12, the opening day of the exhibition – All times are CEST:

Stellantis Press Conference Schedule
Monday, October 12, 2026
Hall 4, Paris Motor Show
Time (CEST)	Brand
9:45 a.m.	Stellantis
9:55 a.m.	Citroën
10:10 a.m.	PEUGEOT
10:25 a.m.	DS Automobiles
10:40 a.m.	Leapmotor
10:55 a.m.	Alfa Romeo
11:10 a.m.	FIAT
11:25 a.m.	Lancia
11:40 a.m.	Opel

# # #

About Stellantis

Stellantis (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com

	@Stellantis		Stellantis		Stellantis		Stellantis
For more information, contact: Alessandro NARDIZZI – alessandro.nardizzi@stellantis.com Fernão SILVEIRA +1 947 252 3969 – fernao.silveira@stellantis.com communications@stellantis.com www.stellantis.com

Attachment

• EN-20260916-Stellantis-Paris-Motor-Show-2026

Industry recognition highlights Safe Harbor’s expertise in helping banks and credit unions build, strengthen and scale cannabis banking programs

DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor (the “Company” or “Safe Harbor”) (NASDAQ: SHFS), a leading provider of cannabis banking infrastructure and compliance solutions for financial institutions, announced that it was named Top Business Solutions Company at the 2026 PBC Awards, presented during the PBC Conference in Washington, D.C.

“Being recognized as PBC’s Top Business Solutions Company reflects the experience and commitment our team brings to this industry every day,” said Terry Mendez, CEO, Safe Harbor. “Financial institutions need support that fits their program, whether they are entering the market or expanding an established business. We help them build, strengthen and scale with the specialized expertise and operational support this industry requires.”

Safe Harbor Institutional served as the official cannabis banking solutions sponsor of the PBC Conference, held Sept. 9 and 10 at the Capital Hilton in Washington. Mendez also delivered keynote remarks and moderated “Scaling Cannabis Banking Programs: Operational Models That Work,” a panel examining how financial institutions can build and manage sustainable cannabis banking programs.

Safe Harbor serves banks and credit unions through Safe Harbor Institutional, its dedicated offering for financial institutions launching, managing or expanding cannabis banking programs. Through Onboarding Support, Co-Managed and Comprehensive engagement models, Safe Harbor Institutional provides services spanning program design, onboarding, customer due diligence, ongoing compliance administration, transaction monitoring, technology and workflows, and audit and examination readiness.

These services can complement an institution’s existing team and technology. Financial institutions retain their customer relationships and deposits, maintain control of their programs, and remain responsible for policies and governance.

Safe Harbor also supports financial institutions in meeting the broader needs of their cannabis customers through lending, payments and business solutions that complement the institution’s banking services and strengthen its customer relationships.

For more information about Safe Harbor Institutional, visit shfinancial.org/institutional.

About Safe Harbor:
Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services, and institutional solutions tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has assisted in the processing of more than $36 billion in cannabis-related depository funds across 41 states and territories since inception. Through its proprietary technology, platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking and compliance infrastructure to long-term growth, Safe Harbor provides real solutions and personal support, built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Cautionary Statement Regarding Forward-Looking Statements:
Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations and guidance relating to Safe Harbor’s services; Safe Harbor’s growth prospects and Safe Harbor’s market size; Safe Harbor’s projected financial and operational performance, including relative to its competitors and historical performance; success or viability of new product and service offerings Safe Harbor may introduce in the future; the impact volatility in the capital markets, which may adversely affect the price of Safe Harbor’s securities; the outcome of any legal proceedings that have been or may be brought by or against Safe Harbor; and other statements regarding Safe Harbor’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:
ir@SHFinancial.org

Safe Harbor Media Relations Contact:
safeharbor@kcsa.com

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President – Commercial, effective September 16, 2026.

Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles at other notable companies.

Brian Donnelly, who has served as Chief Commercial Officer since May of 2025, will be departing Myriad on September 21, 2026.

“I want to thank Brian for his contributions to Myriad,” said Sam Raha, President and CEO of Myriad Genetics. “We are excited to have Vishal lead our commercial organization. His deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of our cancer care continuum focus and profitable growth strategy going forward.”

“I’m energized to lead the commercial organization at this important stage for Myriad,” said Mr. Sikri. “I look forward to partnering with Sam and the executive leadership team to advance Myriad’s mission, serve more patients and healthcare providers, and create increased value for shareholders.”

The company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call on July 30, 2026.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call, and Mr. Sikri’s deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of the company’s Cancer Care Continuum focus and profitable growth strategy going forward. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

CONTACT: Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Andria Rosell
(385) 202-3510 
PR@myriad.com

Six years after Seer’s foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health

REDWOOD CITY, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a pioneer in deep, unbiased proteomics, today announced that its Proteograph® Product Suite has been used by researchers in more than 100 peer-reviewed scientific publications, enabling researchers to uncover differentiated proteomic insights and marking a significant milestone in the emergence of deep proteomics at scale as a new paradigm for biological research.

For decades, proteomics researchers faced a fundamental tradeoff: they could interrogate the proteome deeply or study large numbers of samples, but doing both was impractical. Seer was founded to eliminate that compromise. By combining engineered nanoparticles with mass spectrometry, the Proteograph Product Suite enables researchers to access deep, unbiased proteomic information across large studies with the throughput, reproducibility and economics required for population-scale research.

Six years after Seer first described the approach in a foundational Nature Communications publication, academic, government and industry researchers across three continents have now applied Proteograph technology in more than 100 peer-reviewed studies. The resulting body of work spans genetics, aging, disease biology, biomarker discovery and population health, including publications in Nature, Nature Medicine, Nature Genetics, Nature Communications and Nature Aging.

Many of these studies draw on uniquely valuable cohorts assembled over years or decades and on biospecimens that cannot be replaced, making the ability to extract substantially more biological information from each sample especially important.

“We pioneered a technology that makes deep, unbiased proteomic analysis possible across large cohorts with the scale, speed, robustness and economics needed to unlock the vast biological information in the proteome—from fundamental discovery through translational research and, ultimately, clinical applications,” said Omid Farokhzad, M.D., Chief Executive Officer and Chair of the Board of Seer. “More than 100 peer-reviewed customer publications now demonstrate the impact of that advance, enabling researchers to uncover previously inaccessible biology, connect genetic variation to proteins and disease, and extract far more information from some of the world’s most valuable cohorts. We believe this capability will become even more important in the age of AI, because the next generation of biological models will require enormous quantities of deep, reproducible and information-rich human data. Seer is building the proteomic foundation to generate those datasets at a scale that was simply not possible before.”

Studies conducted with the Proteograph Product Suite include:

• Revealing biology beyond the reach of leading affinity platforms: Claudia Langenberg, M.D., Ph.D., Maik Pietzner, Ph.D., and collaborators at Queen Mary University of London and the Berlin Institute of Health at Charité used the Proteograph Product Suite to profile more than 1,400 British South Asian participants in research published in Nature Genetics. The study identified more than 3,430 proteins not covered by two leading affinity-based platforms and more than 1,200 genetic associations with plasma proteins, over half of which had not previously been reported. By combining deep, unbiased proteomic coverage with population scale, the study demonstrated that the Proteograph can reveal substantial new biology that would otherwise remain inaccessible.
• Bringing greater accuracy to the path from genetics to drug targets and biomarkers: Karsten Suhre, Ph.D., and collaborators from Harvard Medical School/Brigham and Women’s Hospital and TruDiagnostic, used Proteograph in a Nature Genetics study to perform large-scale, peptide-level mass spectrometry proteomics across approximately 1,600 samples. Unlike affinity-based measurements, peptide-level mass spectrometry allowed the researchers to determine whether genetic associations reflected true changes in protein biology or changes in binder recognition caused by protein-altering variants. The study demonstrated how the Proteograph can provide the resolution needed to build more reliable links from genetic variation to proteins, disease mechanisms, drug targets and biomarkers.
• Connecting fundamental aging biology to clinically relevant human phenotypes: Nathan Basisty, Ph.D., and colleagues used Proteograph to deeply characterize the proteins secreted by senescent human monocytes and then connect those signatures to plasma measurements from more than 1,000 participants in the Baltimore Longitudinal Study of Aging. Published in Nature Aging, the study identified circulating senescence-associated proteins linked to multiple age- and obesity-related clinical traits, illustrating how the deep proteomics enabled by the Proteograph can translate cellular mechanisms of aging into measurable signals in humans and potentially inform biomarkers and therapeutic development.

The body of work builds on Seer’s 2020 Nature Communications paper, which demonstrated that proprietary engineered nanoparticles could enable deep, reproducible interrogation of the plasma proteome at scale without preselecting which proteins to measure.

Additional Proteograph-enabled research will be presented at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 in Singapore.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the continued adoption and use of Seer’s Proteograph Product Suite in scientific research; the anticipated presentation and publication of additional Proteograph-enabled research; the future role and importance of deep proteomics, including in AI-driven biological research; and the potential for clinical applications of Seer’s technology. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio

Two-year audit initiative advances Company’s financial-reporting infrastructure and mid-term objective of pursuing qualification for the OTCQX® Best Market

GREEN VALLEY, Ariz., Sept. 16, 2026 (GLOBE NEWSWIRE) — NEXT10, Inc. (OTC: NXTN), together with its operating company Torreon Group, Inc., today announced that it has engaged Victor Mokuolu, CPA PLLC, an independent public accounting firm registered with the Public Company Accounting Oversight Board (“PCAOB”), to conduct audits of Torreon Group, Inc./NEXT10, Inc. financial statements for the fiscal years ended July 31, 2024 and July 31, 2025.

The audit engagement represents an important step in strengthening NEXT10’s financial-reporting, accounting and corporate-governance infrastructure as the Company continues to expand its operating businesses and pursue its longer-term capital-markets strategy.

The audit is expected to be conducted in accordance with applicable PCAOB auditing standards and is intended to provide an independent auditor’s opinion regarding the presentation of the applicable financial statements, in all material respects, under the applicable financial-reporting framework.

Management’s mid-term objective is to position NEXT10 to pursue qualification for the OTCQX^® Best Market, the highest market tier operated by OTC Markets Group, subject to the Company satisfying all applicable financial, reporting, governance, public-float, market-price and other eligibility requirements in effect at the time of any application.

The Company is also working toward developing the accounting and reporting infrastructure necessary to become an SEC-reporting company. These initiatives are part of a broader effort to increase financial transparency, strengthen corporate governance and establish a reporting framework capable of supporting NEXT10’s continued growth.

“Engaging a PCAOB-registered auditor is an important milestone in the continued development of NEXT10 and Torreon Group,” said Garrett Reincke, President of NEXT10, Inc. “As the Company has grown, so has the complexity of our accounting and reporting requirements. Our objective is to establish the disciplined financial-reporting infrastructure and transparency expected of a more mature public company.

“The audit is not the end objective; it is part of the foundation we are building for the next stage of NEXT10,” said John B. Hayden, Chief Executive Officer and Chairman. “Our mid-term capital-markets objective is to position the Company to pursue qualification for OTCQX. Getting there requires stronger financial reporting, governance, operating discipline and transparency, and that is the infrastructure we are putting in place.”

The audit process is expected to include examination of historical financial statements, accounting records and supporting financial information. Completion of the audit will depend on, among other matters, the availability and completeness of historical records, completion of required audit procedures and resolution of any accounting matters identified during the process.

The engagement of a PCAOB-registered auditor does not by itself result in the Company becoming SEC reporting or qualifying for OTCQX, and there can be no assurance regarding the timing or successful completion of either initiative.

About NEXT10, Inc.

NEXT10, Inc. (OTC: NXTN), operating through Torreon Group, Inc. and its affiliated businesses, is a diversified holding and operating company with interests that currently include mining, residential development and homebuilding, distillery operations, and aviation.

The Company’s strategy is to acquire and develop assets and operating businesses, including opportunities backed by real estate or other hard assets, and seek to improve operations and optimize those assets for cash flow. As its portfolio develops, NEXT10 is also strengthening the financial-reporting, governance and corporate infrastructure necessary to support the Company’s long-term growth and capital-markets objectives.

For additional information, visit www.torreongroupinc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the anticipated audit process and completion of audited financial statements; the Company’s efforts to strengthen its financial-reporting, accounting and corporate-governance infrastructure; its objective of becoming an SEC-reporting company; its intention to position itself to pursue qualification for the OTCQX Best Market; and the Company’s business-development and growth strategy.

Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “expect,” “intend,” “objective,” “plan,” “pursue,” “seek,” “will,” “would,” and similar expressions.

These statements are based upon management’s current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the timing, scope and results of the audit; the completeness and availability of historical accounting records; the Company’s ability to complete its financial-reporting and governance initiatives; the Company’s ability to satisfy applicable OTCQX eligibility requirements; changes in applicable securities, accounting or OTC Markets requirements; the Company’s ability to obtain financing on acceptable terms, if at all; risks associated with its operating businesses and development-stage projects; and general economic and market conditions.

The Company is not currently subject to the periodic reporting requirements of the Securities Exchange Act of 1934. There can be no assurance that the Company will become an SEC-reporting issuer, satisfy the requirements for OTCQX qualification or that any future application for OTCQX will be approved.

Forward-looking statements speak only as of the date of this release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect subsequent events or circumstances.

Contact

John B. Hayden
CEO/CHAIRMAN

Investor Relations
ir@torreongroupinc.com

• Advancing titanium beyond batch production: GenX™ has validated continuous HAMR™ processing, advancing beyond the batch model used in conventional Kroll titanium production. Major operating gains support the potential for lower unit costs, higher titanium throughput, and a modular capital-efficient expansion pathway
• Verified oxygen results: All valid product samples met the relevant oxygen benchmark: ASTM Grade 5 for angular powder and the more stringent Grade 23 specification for spherical titanium powder
• Six times throughput volume: Total throughput for the GenX™ furnace was six times the volume of the batch HAMR™ system, on a like-for-like run time basis
• Lower energy intensity: Power consumption reduced by more than 75% versus batch HAMR™ processing
• Substantially lower measured input use: More than 45% less magnesium and over 60% less hydrogen required per kilogram of titanium powder, relative to batch HAMR™
• Further efficiency potential: Operational data highlights potential for far lower capex intensity (installed capital per ton of capacity) and the potential for significantly lower labor unit costs
• Next stage in Q4 2026: IperionX will continue to optimize the current GenX™ furnace; integrate the continuous furnace into a full titanium powder production line; and advance technoeconomic and engineering work for the first industrial-scale GenX™ production line

SOUTH BOSTON, Va., Sept. 16, 2026 (GLOBE NEWSWIRE) — IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to announce that GenX™, its next-generation continuous HAMR™ titanium production platform, has been successfully validated through the first four production campaigns, completed on the commercial-scale GenX™ system at IperionX’s Virginia R&D facility.

GenX™ validation opens a pathway to a step change in titanium production economics. Moving beyond the batch model used in conventional Kroll titanium production, continuous processing offers the potential for higher throughput, significantly lower unit costs, improved equipment utilization and reduced processing time.

Successful testing demonstrates low-oxygen titanium powder production

The GenX™ system processed more than 500 kg of titanium powder across four separate continuous runs totaling 41 hours, at an average rate of approximately 12 kg per hour. Product from each run was collected separately, with samples randomly selected from different locations for oxygen analysis.

Measure	Angular powder		Spherical powder
Starting oxygen	0.250% – 0.323%		0.215%
Product oxygen range	0.104% – 0.144%		0.072% – 0.084%
Average product oxygen	0.126%		0.078%
Relevant oxygen specification	Grade 5: 0.200%       /      Grade 23: 0.130%
Runs and combined duration	2 runs / 18 hours		2 runs / 23 hours
Analyzed samples	7		8

Table 1: GenX™ continuous titanium production results

Seven of the eight angular powder samples collected met the Grade 5 oxygen limit applicable to Ti-6Al-4V plate and bar under ASTM B265 and B348. Four of the eight also met the more stringent Grade 23 oxygen limit. One sample collected during an interrupted furnace run did not complete the HAMR™ cycle and was excluded from the validation assessment. IperionX anticipates that minor process refinements will enable angular powder to meet the Grade 23 oxygen limit. All spherical titanium powder samples met the Grade 23 oxygen limit and therefore also satisfied the Grade 5 oxygen specifications.

GenX™ continuous processing – potential to materially shift the titanium cost curve

The patented HAMR™ process is IperionX’s hydrogen-enabled, low-temperature process for low-oxygen titanium powder, currently in operation on a batch basis in Virginia. GenX™ applies that process continuously, eliminating the repeated furnace heat-up, cool-down, loading and unloading time inherent in batch cycles. Measured GenX™ data has firmly established the potential to materially reduce the cost base for HAMR™ titanium production.

Operating measure	Measured GenX result	Comparison basis (batch HAMR)1
Magnesium consumption	>45% lower	Per kg
Hydrogen consumption	>60% lower	Per kg
Power consumption	>75% lower	Per kg
Processing time	6 times throughput	Like-for-like run time

      1. Actual operating data based upon current batch HAMR operations

Table 2: GenX™ measured inputs and throughput compared to batch HAMR™

All comparisons are measured results against the batch HAMR™ reference; power use was measured directly on the GenX™ system. Magnesium is HAMR’s largest reagent cost, and lower use also reduces the by-product requiring downstream leaching and handling, which will be evaluated and quantified in further production campaigns.

Continuous GenX™ operation is expected to improve equipment utilization, eliminate ancillary process steps and support expansion through replicated and scaled-up production lines. Operational data highlights the potential for far lower installed capital per ton of annual capacity, and IperionX estimates significant potential labor cost savings.

Engineering the next stage

During Q4 2026, IperionX will continue to run and optimize the GenX™ furnace, integrate the current furnace into a full powder production line; and conduct technoeconomic and engineering evaluation for the first industrial-scale GenX™ production line. GenX™ remains a high capacity, low cost development platform but is not required to achieve low cost production for the existing 200 tpa production ramp or planned expansions in Virginia. Similar industrial scale furnace types in service are achieving throughputs measured in 1000s of tons per annum per unit.

GenX™ also complements continuous HSPT™ development, supporting a pathway from continuous titanium powder production to finished titanium components. U.S. Army Task Order 2, awarded on August 31, 2026 under IperionX’s US$99 million SBIR Phase III contract, funds a continuous HSPT™ development furnace and industrial-scale continuous HSPT™ and dehydrogenation capacity in Virginia.

IperionX CEO Taso Arima said:

“Achieving continuous primary titanium production has long been the ultimate aspiration for the titanium industry. IperionX’s GenX™ process is a continuous titanium production platform that is more efficient to operate and easier to scale. These first results exceeded our expectations: more than 500 kilograms of recycled titanium powder processed across four separate runs, with every sample meeting its relevant oxygen specification.

Substantially lower magnesium, hydrogen and power consumption at steady state, together with processing throughput increasing by six times, give us a strong basis for industrial development. Our next step is the engineering and economic evaluation of the first industrial-scale GenX™ production line. We aim to establish a scalable platform for expansion that lowers production costs and brings titanium within reach of a broader range of applications.”

About IperionX

IperionX is a leading American titanium metal and critical materials company – using patented metal technologies to produce high performance titanium alloys, from titanium minerals or scrap titanium, at lower energy, cost and carbon emissions.

Our Titan critical minerals project is the largest JORC-compliant mineral resource of titanium, rare earth and zircon mineral sands in the United States.

IperionX’s titanium metal and critical minerals are essential for advanced U.S. industries including space, aerospace, defense, consumer electronics, hydrogen, automotive and additive manufacturing.

Forward Looking Statements

Information included in this release constitutes forward-looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation, statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs.

Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, and achievements to differ materially from any future results, performance, or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, foreign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary licenses and permits and diminishing quantities or grades of reserves, the Company’s ability to comply with the relevant contractual terms to access the technologies, commercially scale its closed-loop titanium production processes, or protect its intellectual property rights, political and social risks, changes to the regulatory framework within which the Company operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations issues and litigation.

Forward looking statements are based on the Company and its management’s good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the future. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company’s control.

Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements, or events not to be as anticipated, estimated or intended, and many events are beyond the reasonable control of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under applicable law or any relevant stock exchange listing rules, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Contacts

Anastasios (Taso) Arima, Founder and CEO
Toby Symonds, President
Dominic Allen, Chief Commercial Officer

Investors: investorrelations@iperionx.com
Media: media@iperionx.com

+1 980 237 8900
www.iperionx.com

QUANZHOU, China, Sept. 16, 2026 (GLOBE NEWSWIRE) — INLIF LIMITED (NASDAQ: INLF) (together with all its subsidiaries and consolidated entities, the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced the results of the Company’s Extraordinary General Meeting (the “Meeting”) held at 9:30 a.m. U.S. Eastern Time on September 15, 2026. The proposals submitted for shareholder approval at the Meeting have been approved. Specifically, the shareholders have duly passed the following resolutions:

(1) Share Capital Increase. To approve, by ordinary resolution, the increase of the authorized share capital of the Company from US$350,000, divided into 1,046,875 Class A ordinary shares and 46,875 Class B ordinary shares of par value US$0.32 each, to US$2,720,000,000, divided into 8,000,000,000 Class A ordinary shares and 500,000,000 Class B ordinary shares of par value US$0.32 each, requiring the creation of an additional 7,998,953,125 Class A ordinary shares and 499,953,125 Class B ordinary shares of par value US$0.32 each.

(2) Adoption of the Seventh Amended and Restated Memorandum and Articles of Association. To adopt, by special resolution and conditional upon and immediately following the Share Capital Increase, the seventh (7^th) amended and restated memorandum and articles of association, substantially in the form attached as Exhibit A to the explanatory statement accompanying the notice of the Meeting previously distributed to the shareholders, primarily to reflect the Share Capital Increase, to amend Article 11.1(b) to base the quorum requirement on voting power rather than the number of shares, and to reflect certain other housekeeping changes.

(3) Share Capital Reorganization. To approve, by special resolution, the reduction of the par value of each authorized ordinary share from US$0.32 to US$0.0001, through the steps described in the explanatory statement accompanying the notice of the Meeting previously distributed to the shareholders, and to authorize the Board of Directors to take all actions necessary or advisable to effect such change, conditional upon and immediately following the Share Capital Increase and subject to compliance with Sections 14, 14A, and 14B of the Companies Act (Revised) of the Cayman Islands.

(4) Adoption of Amended and Restated Memorandum and Articles of Association to Reflect the Share Capital Reorganization. To adopt, by special resolution, an amended and restated memorandum and articles of association reflecting the Share Capital Reorganization, conditional upon and immediately following the Share Capital Reorganization being effected.

(5) Migration to the British Virgin Islands. To approve, by special resolution, the deregistration of the Company as an exempted company under the laws of the Cayman Islands and its continuation into the British Virgin Islands as a BVI business company (the “Migration”); to authorize any Director to sign the voluntary declaration (including a statement of the Company’s assets and liabilities as required by the Companies Act (Revised)), an undertaking that the Company has no secured creditors, and a notice of the proposed BVI registered office address, each in connection with the application to the Cayman Islands Registrar of Companies; to approve the adoption, conditional upon and with immediate effect from the Migration, of a BVI-compliant memorandum and articles of association (the “BVI MAA”), substantially in the form attached as Exhibit B to the explanatory statement accompanying the notice of the Meeting previously distributed to the shareholders, to replace the Company’s existing memorandum and articles of association in their entirety; and to authorize the Board of Directors and any director or officer to take all actions, execute all documents, and make all filings necessary or desirable to effect the Migration. The proposal was expressed to be subject to all necessary governmental and regulatory consents.

(6) Ratification of Independent Registered Public Accounting Firm. To ratify, by ordinary resolution, the appointment of Enrome LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

(7) Adjournment. To approve, by ordinary resolution, the adjournment of the Meeting, if necessary.

The approved proposals will take effect in such sequence and subject to such conditions reviewed at the Meeting and described in the notice and explanatory statement, including any required governmental and regulatory consents and filings.

The Meeting was held originally on September 8 at 9:30 a.m. U.S. Eastern Time, and was adjourned due to the absence of a quorum and in accordance with the adjourned-meeting provisions of Article 11.2(b) of the Company’s currently effective sixth amended and restated memorandum and articles of association. The ordinary shares represented in person or by proxy at this adjourned Meeting, although still less than one-third (1/3) of the outstanding ordinary shares, constituted a quorum in accordance with Article 11.2(b) as permitted under applicable Cayman Islands law. In this respect, the Company elected to follow home country practice in the Cayman Islands in lieu of satisfying the quorum-related requirements of Nasdaq’s Listing Rule 5620(c).

About INLIF LIMITED
INLIF is a holding company and an exempted company incorporated in the Cayman Islands with limited liability. Through its operating entity in the People’s Republic of China, Ewatt Robot Equipment Co. Ltd., established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. It is also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms, all developed by itself. It has also built experience in industrial automation solutions, including in the new energy sector, as well as intelligent robotics in recent years. For more information, please visit the Company’s website: https://ir.yiwate88.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements also involve other known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “aims,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries, please contact:

INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com 

SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) — Delixy Holdings Limited (Nasdaq: DLXY) (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced that on September 15, 2026, the Company entered into a non-binding letter of intent (the “LOI”) with Caog S.a.r.l, a Luxembourg registered company, for acquisition or merger of up to 48% of shares in Tarbagatay Munay (“TBM”), a Kazakhstan registered company and the subsoil user and operator of the oil and gas project of Sarybulak Oil Field in East Kazakhstan (the “Project”).

Pursuant to the proposed terms of the LOI, Delixy intends to evaluate two potential transaction schemes: (i) an acquisition of part or all of the equity of the Project operating company to obtain the operating right, profit right and development right of the Project; or (ii) an asset merger and restructuring involving the Project’s operational assets, pipeline facilities, mineral right reserves and production and operation business to realize integrated cooperative operation.

The Project is a gas and crude oil upstream exploitation and production company located approximately 90 kilometers from the China-Kazakhstan border, providing strategic access to one of the region’s key energy transportation corridors. The Project has maintained a stable and continuous supply of natural gas to China for more than thirteen years through a self-owned cross-border pipeline, delivering an aggregate of close to 4.0 billion cubic meters by the end of April 2026.

In addition to its established gas production operations, the Project has recently expanded into crude oil production, with commercial oil sales commencing in the first quarter of 2026. TBM currently has approximately 100 million metric tons of approved original oil in place (“OOIP”) recognized by the Kazakhstan Geological Committee. Ongoing geological exploration and resource evaluation activities have identified additional oil-bearing formations within the Project area, which are expected to further enhance the Project’s resource scale and asset value.

The Project’s crude production so far consists mainly of heavy naphthenic crude oil, which is a desirable feedstock for producing special naphthenic base oil used in lubricant applications, typically of higher value than conventional fuel products.¹ Recent exploration in the Project area has also indicated several light oil-bearing structures, which are anticipated to facilitate the development of lighter crude oil and support production diversification.

The Project also possesses full oil export rights, providing flexibility to access international markets.

Mr. Dongjian Xie, Executive Chairman and Chief Executive Officer of Delixy, commented, “The proposed transaction represents a significant step in Delixy’s strategy to expand beyond oil trading and strengthen our participation across the energy value chain. Through its privately owned cross-border pipeline, the Project can deliver its produced crude oil to China, Delixy’s main crude market, where we maintain a strong network of commercial relationships and influence over the crude end users. We believe this strategic alignment of the Project’s upstream assets with Delixy’s established marketing capabilities can enhance commercialization opportunities and support long-term value creation.

Mr. Xie continued, “The Project combines strong relationships with local government, long-established natural gas production, existing cross-border energy infrastructure, newly commenced crude oil production, and substantial resource potential within a strategically important region adjacent to the Chinese market. We believe this opportunity could enhance our supply chain integration, diversify our revenue streams, and create additional long-term value for our shareholders. We look forward to working closely with our prospective partner to advance this opportunity.”

Completion of the transaction is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the Company’s board. In addition, any definitive transaction will be subject to, among other conditions, (i) receipt of all required Kazakhstan governmental, regulatory and subsoil-authority approvals, including any waiver of the State’s statutory priority or pre-emptive right over a transfer of the subsoil use right or a change of control of the subsoil user, and (ii) the consent of, and the waiver of any pre-emptive, right-of-first-refusal, tag-along or similar rights held by, the other shareholder(s) of TBM. Accordingly, there can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated.

About Tarbagatay Munay

TBM is a Kazakhstan registered company and the subsoil user and operator of oil and gas project of Sarybulak Oil Field in East Kazakhstan. The Project is located near the China-Kazakhstan border, benefit from established cross-border energy infrastructure and export capabilities. TBM is currently owned by Caog S.a.r.l and a China public listed company in Shanghai Stock Exchange. It has been operating in the region for more than fifteen years and has built mutually respected relationships with the Kazakhstan government.

About Delixy Holdings Limited

Delixy Holdings Limited is a Singapore-based company principally engaged in the trading of oil-related products, including (i) crude oil and (ii) oil-based products such as fuel oil, motor gasoline, additives, gas oil, base oil, asphalt, naphtha (heavy gasoline) and petrochemicals. Operating across multiple countries in Southeast Asia, East Asia, and Middle East, Delixy has established a strong presence in the region’s oil trading markets. While Delixy maintains a diversified portfolio of oil products, crude oil trading represents a core aspect of its business. The Company leverages its strong existing relationships with customers and suppliers as well as deep industry expertise to provide value-added services, including tailored recommendations on optimal trading strategies and shipping and logistical support where required. In addition, the Company’s financing capabilities allow it to extend credit terms to customers while satisfying suppliers’ immediate payment terms. For more information, please visit the Company’s website: https://ir.delixy.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”, “estimate”, “will”, “aim” and “anticipate” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (the “SEC”).

For media inquiries, please contact:

Delixy Holdings Limited
Investor Relations Department
Email: ir@delixy.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

---

1 Sources: Guanghui Energy company news (2024), http://www.xjguanghui.com/Typ.aspx?id=0301&Type=XWZX_GSYW&nid=4311; Shanghai Securities News (September 14, 2013), https://www.cnfin.com/stock-xh08/a/20130914/1248157.shtml.

Sold-out MAMAMOO Hong Kong concert supports Globavend’s horizontal expansion into live events; Southeast Asian live entertainment market projected to reach US$10 billion by 2034

PERTH, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) — via IBN — Globavend Holdings Limited (NASDAQ: GVH) (“Globavend” or the “Company”), an emerging AI-powered digital entertainment company and e-commerce logistics provider, today announced the expansion of its digital entertainment platform into the live entertainment business through its subsidiary, Loomi Entertainment Group Limited (“Loomi”).

Loomi will organize the 2026 OK TAECYEON FANMEETING IN MACAU ‘TodaY’ on Nov. 14, 2026, at The Grand Hall, Grand Lisboa Palace Resort Macau. The event will mark K-pop star OK TAECYEON’s first solo fan meeting in Macau and Globavend’s first organizer-led live entertainment event outside Hong Kong.

The expansion builds on Globavend’s strategic investment and co-organizer role in the MAMAMOO 2026 WORLD TOUR <4WARD> Hong Kong, for which all tickets made available have sold out.

Globavend believes the sold-out MAMAMOO concert and the upcoming OK TAECYEON fan meeting demonstrate the potential to extend its existing digital entertainment operations horizontally into concerts, fan meetings and other live experiences.

Independent industry research estimates that the Southeast Asian live entertainment market was valued at approximately US$5.97 billion in 2025 and is projected to reach approximately US$10 billion by 2034, representing a compound annual growth rate of approximately 5.87% from 2026 to 2034. Music concerts were the market’s largest event segment in 2025.

Expanding from Digital Content to Live Entertainment

Through Loomi, Globavend has established digital entertainment capabilities spanning intellectual-property development, AI-assisted content production, multilingual content distribution and mobile streaming.

The Company’s expansion into live entertainment adds a new complementary business vertical covering event investment, organization and promotion. Globavend expects the expansion to increase its participation across the entertainment value chain and create potential revenue opportunities from ticket sales, sponsorships, merchandising, artist collaborations, content rights and intellectual-property commercialization.

“Our expansion into live entertainment is a natural extension of Globavend’s digital entertainment strategy,” said Kenny K. M. Fung, Chairman of Globavend. “We are moving beyond the creation and distribution of digital content to participate directly in live experiences that connect artists with audiences.”

“The sold-out MAMAMOO Hong Kong concert provides encouraging validation of regional demand for premium Asian entertainment,” Fung continued. “By organizing OK TAECYEON’s first solo fan meeting in Macau, we are advancing from strategic investment and co-organization to direct event organization, further broadening our operating capabilities and commercial participation.”

Globavend believes its digital and live entertainment businesses can generate complementary opportunities. Digital content and distribution channels may support artist promotion, localized marketing and audience development, while live events may generate new content, commercial partnerships and longer-term fan engagement across digital platforms.

Building on Sold-Out MAMAMOO Ticket Sales

Globavend entered the live entertainment sector through Loomi’s strategic investment in the MAMAMOO 2026 WORLD TOUR <4WARD> Hong Kong. Loomi serves as an official co-organizer of the concert and is entitled to a pro rata share of its economic returns based on its capital contribution.

All tickets made available for the MAMAMOO Hong Kong concert have sold out. The concert is scheduled for Oct. 4, 2026, at Kai Tak Arena in Hong Kong.

The ticket sell-out represents an important commercial milestone for Globavend’s entertainment strategy and strengthens Loomi’s relationships with artists, talent agencies, promoters, venues, sponsors and other entertainment-industry partners.

With the OK TAECYEON fan meeting, Loomi is expanding its role from investor and co-organizer to organizer. This progression is expected to give the Company broader exposure to the commercial and operational components of live entertainment.

Macau Establishes First Organizer-Led Regional Footprint

Macau will become Globavend’s first organizer-led live entertainment footprint outside Hong Kong and the initial step in its planned expansion across Greater China and Southeast Asia.

The Company believes Macau’s tourism infrastructure, integrated resorts, international visitor base and proximity to major population centers in the Greater Bay Area make it an attractive market for concerts, fan meetings and premium entertainment experiences.

Globavend intends to use the Macau event to strengthen its event-management capabilities and regional network of artists, talent agencies, promoters, venues, sponsors and ticketing partners. The Company plans to evaluate further opportunities across Southeast Asia based on audience demand, artist appeal, venue infrastructure, local partnerships, regulatory requirements and anticipated commercial returns.

“Macau provides a strategic first footprint for the regional expansion of our live entertainment business,” Fung said. “Our objective is to develop a scalable platform capable of organizing, investing in and commercializing premium entertainment experiences across Greater China, Southeast Asia and other selected Asian markets.”

Targeting a US$5.97 Billion Addressable Market

Independent industry research valued the Southeast Asian live entertainment market at approximately US$5.97 billion in 2025 and projects that it will grow to approximately US$10 billion by 2034.

Globavend believes this addressable market is supported by rising disposable incomes, expanding venue infrastructure, increased spending on experiences, a young and digitally engaged population and growing international demand for Asian music, television and film talent.

The Company’s potential addressable opportunities extend beyond event ticket sales to sponsorships, merchandise, artist partnerships, content production, intellectual-property rights and technology-enabled fan engagement.

Globavend currently operates Loomi: Short Drama, a mobile streaming platform offering professionally produced multilingual micro dramas, and Imaginary, its proprietary AI-powered cinematic production platform. The Company intends to explore opportunities to apply these capabilities to the live entertainment business through promotional content, localized audience engagement, post-event media and digital commercialization.

“Our strategy is to build an integrated entertainment ecosystem spanning digital content, proprietary technology, distribution and live experiences,” Fung concluded. “We believe this horizontal expansion gives Globavend access to a broader addressable market and multiple potential revenue channels across the entertainment value chain.”

About the 2026 OK TAECYEON FANMEETING IN MACAU ‘TodaY’

OK TAECYEON is a member of iconic K-pop group 2PM and an acclaimed actor whose career spans music, television and film. His performances and internationally distributed screen roles have attracted a substantial following across Asia and other global markets.

The 2026 OK TAECYEON FANMEETING IN MACAU ‘TodaY’ will take place on Nov. 14, 2026, at The Grand Hall, Grand Lisboa Palace Resort Macau. The event forms part of his 2026 Asia fan meeting tour and will feature live performances and fan-engagement activities.

Additional event and ticketing information will be announced through the event’s official channels. For more information, please visit https://www.loomi.asia/news/ok-taecyeon-fanmeeting-macau-live-entertainment-expansion.

About Globavend Holdings Limited

Globavend Holdings Limited (NASDAQ: GVH) is an emerging e-commerce logistics provider and AI-powered digital entertainment company. As a logistics provider, the Company offers integrated cross-border logistics solutions across Hong Kong, Australia, New Zealand and mainland China. As a digital entertainment company, the Company develops generative AI-assisted cinematic production workflows, multimodal content generation capabilities and multilingual digital entertainment distribution solutions through its proprietary AI technologies. It operates Loomi: Short Drama, a mobile streaming platform offering professionally produced multilingual micro dramas, and Imaginary, its proprietary AI-powered cinematic production platform, providing end-to-end AI-assisted content creation capabilities. By combining AI-powered production technologies with proprietary distribution capabilities, Globavend is building an integrated digital entertainment ecosystem while continuing to expand its established cross-border logistics business.

Forward-Looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the anticipated benefits and commercial potential of the OK TAECYEON fan meeting; the Company’s horizontal expansion into live entertainment; potential revenue opportunities; geographical expansion across different markets; anticipated market growth; future concerts, fan meetings, investments and partnerships; and the integration of live entertainment with the Company’s digital content, technology and distribution capabilities.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include the Company’s ability to organize and commercialize live events successfully; changes in artist availability, audience demand and consumer behavior; ticket-sales and event-operating risks; the Company’s ability to establish regional partnerships and enter new markets; competition; intellectual-property and regulatory risks; global economic conditions; changes in operating plans or funding requirements; and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended September 30, 2025, and subsequent reports filed with the U.S. Securities and Exchange Commission.

Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes the expectations reflected in these statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to update any forward-looking statement.

For investor and media inquiries:

Globavend Holdings Limited
Kenny K. M. Fung, Chairman
kennyfung@risemindtech.com
888.201.1623
https://globavend.com